CoChat

Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates

Open access
Pettit, Steve C, Lindquist, Jeffrey N, Kaplan, Andrew H, Swanstrom, Ronald · 2005 · Retrovirology
Cited by 141

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

We have examined the kinetics of processing of the HIV-1 Gag-Pro-Pol precursor in an in vitro assay with mature protease added in trans. The processing sites were cleaved at different rates to produce distinct intermediates. The initial cleavage occurred at the p2/NC site. Intermediate cleavages occurred at similar rates at the MA/CA and RT/IN sites, and to a lesser extent at sites upstream of RT. Late cleavages occurred at the sites flanking the protease (PR) domain, suggesting sequestering of these sites. We observed paired intermediates indicative of half- cleavage of RT/RH site, suggesting that the RT domain in Gag-Pro-Pol was in a dimeric form under these assay conditions. These results clarify our understanding of the processing kinetics of the Gag-Pro-Pol precursor and suggest regulated cleavage. Our results further suggest that early dimerization of the PR and RT domains may serve as a regulatory element to influence the kinetics of processing within the Pol domain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1742-4690-2-66

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 49

  1. Craven RC, Bennett RP, Wills JW: Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol. 1991, 65: 6205-6217. · DOI · Paper page
  2. Stewart L, Vogt VM: Reverse transcriptase and protease activities of avian leukosis virus Gag-Pol fusion proteins expressed in insect cells. J Virol. 1993, 67: 7582-7596. · doi:10.1128/jvi.67.12.7582-7596.1993
  3. Swanstrom R, Wills J: Retroviral gene expression: Synthsis, processing, and assembly of viral proteins. Retroviruses. Edited by: Varmus HE, Coffin JM and Hughes SH. 1997, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 263-334.
  4. Xiang Y, Ridky TW, Krishna NK, Leis J: Altered Rous sarcoma virus Gag polyprotein processing and its effects on particle formation. J Virol. 1997, 71: 2083-2091. · DOI
  5. Gross I, Hohenberg H, Wilk T, Wiegers K, Grattinger M, Muller B, Fuller S, Krausslich HG: A conformational switch controlling HIV-1 morphogenesis. Embo J. 2000, 19: 103-113. 10.1093/emboj/19.1.103. · DOI · Paper page
  6. Joshi SM, Vogt VM: Role of the Rous sarcoma virus p10 domain in shape determination of gag virus-like particles assembled in vitro and within Escherichia coli. J Virol. 2000, 74: 10260-10268. 10.1128/JVI.74.21.10260-10268.2000. · DOI · Paper page
  7. Craven RC, Leure PA, Erdie CR, Wilson CB, Wills JW: Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein. J Virol. 1993, 67: 6246-6252. · DOI · Paper page
  8. Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, Klein CA, Swanstrom R: The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol. 1994, 68: 8017-8027. · DOI · Paper page
  9. Vogt VM: Proteolytic processing and particle maturation. Curr Top Microbiol Immunol. 1996, 214: 95-131.
  10. Sheng N, Pettit SC, Tritch RJ, Ozturk DH, Rayner MM, Swanstrom R, Erickson VS: Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease. J Virol. 1997, 71: 5723-5732. · DOI
  11. Pettit SC, Henderson GJ, Schiffer CA, Swanstrom R: Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol. 2002, 76: 10226-10233. 10.1128/JVI.76.20.10226-10233.2002. · DOI · Paper page
  12. Mervis RJ, Ahmad N, Lillehoj EP, Raum MG, Salazar FH, Chan HW, Venkatesan S: The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors. J Virol. 1988, 62: 3993-4002. · DOI · Paper page
  13. Gowda S, Stein B, Engleman E: Identification of protein intermediates in the processing of the p55 HIV-1 Gag precursor in cells infected with recombinant vaccinia virus. J Biol Chem. 1989, 264: 8459-8462. · DOI · Paper page
  14. Krausslich HG, Ingraham RH, Skoog MT, Wimmer E, Pallai PV, Carter CA: Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc Natl Acad Sci USA. 1989, 86: 807-811. · DOI · Paper page
  15. Lindhofer H, von der Helm K, Nitschko H: In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes. Virology. 1995, 214: 624-627. 10.1006/viro.1995.0074. · DOI
  16. Almog N, Roller R, Arad G, Passi EL, Wainberg MA, Kotler M: A p6Pol-protease fusion protein is present in mature particles of human immunodeficiency virus type 1. J Virol. 1996, 70: 7228-7232. · DOI
  17. Veronese FD, Copeland TD, DeVico AL, Rahman R, Oroszlan S, Gallo RC, Sarngadharan MG: Characterization of highly immunogenic p66/51 as the reverse transcriptase of HTLV-III/LAV. Science. 1986, 231: 1289-1291. · DOI · Paper page
  18. Copeland TD, Oroszlan S: Genetic locus, primary structure, and chemical synthesis human immunodeficiency virus protease. Gene Anal Tech. 1988, 5: 109-115. 10.1016/0735-0651(88)90010-6. · DOI
  19. Chattopadhyay D, Evans DB, Deibel MR, Vosters AF, Eckenrode FM, Einspahr HM, Hui JO, Tomasselli AG, Zurcherneely HA, Heinrikson RL, Sharma SK: Purification and Characterization of Heterodimeric Human Immunodeficiency Virus Type-1 (HIV-1) Reverse Transcriptase Produced by Invitro Processing of P66 with Recombinant HIV-1 Protease. J Biol Chem. 1992, 267: 14227-14232. · DOI
  20. Tomasselli AG, Sarcich JL, Barrett LJ, Reardon IM, Howe WJ, Evans DB, Sharma SK, Heinrikson RL: Human immunodeficiency virus type-1 reverse transcriptase and ribonuclease H as substrates of the viral protease. Protein Sci. 1993, 2: 2167-2176. · DOI
  21. Reil H, Kollmus H, Weidle UH, Hauser H: A heptanucleotide sequence mediates ribosomal frameshifting in mammalian cells. J Virol. 1993, 67: 5579-5584. · DOI
  22. Bebenek K, Kunkel TA: The use of native T7 DNA polymerase for site-directed mutagenesis. Nucleic Acids Res. 1989, 17: 5408- · DOI
  23. Kunkel TA, Bebenek K, McClary J: Efficient site-directed mutagenesis using uracil-containing DNA. Methods Enzymol. 1991, 204: 125-139. · DOI · Paper page
  24. Gorelick RJ, Henderson LE: Part III: Analyses. Human Retroviruses and AIDS. Edited by: Myers G, Korber B, Wain-Hobson S, Jeang KT, Henderson L and Pavlakis G. 1994, Los Alamos, NM, The Los Alamos National Laboratory, 2-5.
  25. Pettit SC, Gulnik S, Everitt L, Kaplan AH: The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage. J Virol. 2003, 77: 366-374. 10.1128/JVI.77.1.366-374.2003. · DOI · Paper page
  26. Moody MD, Pettit SC, Shao W, Everitt L, Loeb DD, Hutchison C, Swanstrom R: A side chain at position 48 of the human immunodeficiency virus type-1 protease flap provides an additional specificity determinant. Virology. 1995, 207: 475-485. 10.1006/viro.1995.1107. · doi:10.1006/viro.1995.1107
  27. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacterophage T4. Nature (London). 1970, 277: 680-685. 10.1038/227680a0. · DOI · Paper page
  28. Schagger H, von Jagow G: Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987, 166: 368-379. 10.1016/0003-2697(87)90587-2. · DOI · Paper page
  29. Phylip LH, Griffiths JT, Mills JS, Graves MC, Dunn BM, Kay J: Activities of precursor and tethered dimer forms of HIV proteinase. Adv Exp Med Biol. 1995, 362: 467-472. · doi:10.1007/978-1-4615-1871-6_61
  30. Louis JM, Dyda F, Nashed NT, Kimmel AR, Davies DR: Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease. Biochemistry. 1998, 37: 2105-2110. 10.1021/bi972059x. · DOI
  31. Chen N, Morag A, Almog N, Blumenzweig I, Dreazin O, Kotler M: Extended nucleocapsid protein is cleaved from the Gag-Pol precursor of human immunodeficiency virus type 1. J Gen Virol. 2001, 82: 581-590. · DOI
  32. Pettit S, Everitt L, Choudhury S, Dunn BM, Kaplan AH: Initial cleavage of the HIV-1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J Virol. 2004, 78: 8477-8485. 10.1128/JVI.78.16.8477-8485.2004. · DOI · Paper page
  33. Pettit SC, Clemente JC, Jeung JA, Dunn BM, Kaplan AH: Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease. J Virol. 2005, 79: 10601-10607. 10.1128/JVI.79.16.10601-10607.2005. · DOI · Paper page
  34. Lightfoote MM, Colisan JE, Folks TM, Fauci AS, Martin MA, Venkatesan S: Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol. 1986, 60: 771-775. · DOI · Paper page
  35. Goobar-Larsson L, Backbro K, Unge T, Bhikhabhai R, Vrang L, Zhang H, Orvell C, Strandberg B, Oberg B: Disruption of a salt bridge between Asp 488 and Lys 465 in HIV-1 reverse transcriptase alters its proteolytic processing and polymerase activity. Virology. 1993, 196: 731-738. 10.1006/viro.1993.1530. · doi:10.1006/viro.1993.1530
  36. Navarro JM, Damier L, Boretto J, Priet S, Canard B, Querat G, Sire J: Glutamic residue 438 within the protease-sensitive subdomain of HIV-1 reverse transcriptase is critical for heterodimer processing in viral particles. Virology. 2001, 290: 300-308. 10.1006/viro.2001.1188. · doi:10.1006/viro.2001.1188
  37. Sluis-Cremer N, Arion D, Abram ME, Parniak MA: Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation. Int J Biochem Cell Biol. 2004, 36: 1836-1847. 10.1016/j.biocel.2004.02.020. · DOI
  38. Weber IT: Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases. J Biol Chem. 1990, 265: 10492-10496. · DOI
  39. Hill MK, Hooker CW, Harrich D, Crowe SM, Mak J: Gag-Pol supplied in trans is efficiently packaged and supports viral function in human immunodeficiency virus type 1. J Virol. 2001, 75: 6835-6840. 10.1128/JVI.75.15.6835-6840.2001. · DOI
  40. Carter CA: Tsg101: HIV-1's ticket to ride. Trends Microbiol. 2002, 10: 203-205. 10.1016/S0966-842X(02)02350-8. · DOI
  41. Goff A, Ehrlich LS, Cohen SN, Carter CA: Tsg101 control of human immunodeficiency virus type 1 Gag trafficking and release. J Virol. 2003, 77: 9173-9182. 10.1128/JVI.77.17.9173-9182.2003. · DOI · Paper page
  42. Ono A, Freed EO: Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol. 2004, 78: 1552-1563. 10.1128/JVI.78.3.1552-1563.2004. · DOI · Paper page
  43. Halwani R, Khorchid A, Cen S, Kleiman L: Rapid localization of Gag/GagPol complexes to detergent-resistant membrane during the assembly of human immunodeficiency virus type 1. J Virol. 2003, 77: 3973-3984. 10.1128/JVI.77.7.3973-3984.2003. · DOI · Paper page
  44. Krausslich HG: Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc Natl Acad Sci USA. 1991, 88: 3213-3217. · DOI · Paper page
  45. Krausslich HG: Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation. J Virol. 1992, 66: 567-572. · DOI
  46. Gatlin J, Arrigo SJ, Schmidt MG: Regulation of intracellular human immunodeficiency virus type-1 protease activity. Virology. 1998, 244: 87-96. 10.1006/viro.1998.9083. · DOI
  47. Wondrak EM, Louis JM, de RH, Chermann JC, Roques BP: The gag precursor contains a specific HIV-1 protease cleavage site between the NC (P7) and P1 proteins. Febs Letters. 1993, 333: 21-24. 10.1016/0014-5793(93)80367-4. · doi:10.1016/0014-5793(93)80367-4
  48. Henderson LE, Sowder RC, Copeland TD, Oroszlan S, Benveniste RE: Gag precursors of HIV and SIV are cleaved into six proteins found in the mature virions. J Med Primatol. 1990, 19: 411-419. · doi:10.1111/j.1600-0684.1990.tb00446.x
  49. Leis J, Baltimore D, Bishop JM, Coffin J, Fleissner E, Goff SP, Oroszlan S, Robinson H, Skalka AM, Temin HM, Vogt VM: Standardized and simplified nomenclature for proteins common to all retroviruses. J Virol. 1988, 62: 1808-1809. · DOI · Paper page

Cited by

See all 141

Metadata

Authors
Pettit, S. C., Lindquist, J. N., Kaplan, A. H., & Swanstrom, R.
Venue
Retrovirology
Published
2005-11-01
Volume
2
Issue
1
Pages
66-66
ISSN
1742-4690 (ISSN-L)
OpenAlex
W2112727291
Cited by
141
References
6
FWCI
1.43
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. https://app.cochat.ai/papers/10.1186/1742-4690-2-66
The paper
Pettit, S. C., Lindquist, J. N., Kaplan, A. H., & Swanstrom, R. (2005). Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology. https://doi.org/10.1186/1742-4690-2-66

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.